Prosecution Insights
Last updated: April 19, 2026
Application No. 18/034,625

REAGENT, KIT AND METHOD FOR STORING URINE SAMPLE

Non-Final OA §102
Filed
Apr 28, 2023
Examiner
RAMIREZ, ALEX
Art Unit
1798
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Healthcare Systems Co. Ltd.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
3y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
90 granted / 114 resolved
+13.9% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
43 currently pending
Career history
157
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
43.3%
+3.3% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
31.2%
-8.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 114 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-5 in the reply filed on 01/05/2026 is acknowledged. Claims 6-10 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected group, there being no allowable generic or linking claim. Information Disclosure Statement The information disclosure statements (IDS) submitted on 04/28/2023 and 12/30/2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the Examiner. Claims Status Claims 1-10 are pending with claims 1-5 being examined and claims 6-10 deemed withdrawn. . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yamagata (JPH 08201382 A; see English translation; hereinafter “Yamagata” previous of record). Regarding claim 1, Yamagata teaches a reagent for preserving a urine specimen, comprising a filter paper (Yamagata; Abstract), wherein the filter paper comprises an aromatic alcohol, a phenol derivative, or a polyhydric fatty alcohol (Yamagata; [0009]). Regarding claim 2, Yamagata teaches the reagent according to claim 1 (see above), wherein the content of the aromatic alcohol, phenol derivative, or polyhydric fatty alcohol in the filter paper is 0.5 to 100 mg per mL of a urine specimen to be applied (Yamagata; [0009] “phenol”). Regarding claim 3, Yamagata teaches the reagent for preserving a urine specimen according to claim 1 (see above), wherein the filter paper comprises phenoxyethanol (Yamagata; [0009] teaches “the antibacterial agent to be contained in the filter can be any agent that has antibacterial affect”). Phenoxyethanol is known in the art to have antibacterial effect (Drugbank.com), therefore Yamagata meets the limitation. Regarding claim 4, Yamagata teaches the reagent according to claim 3 (see above), wherein the content of phenoxyethanol in the filter paper is 1.0 to 50 mg per mL of a urine specimen to be applied (Yamagata; [0009] teaches the antibacterial agent to be contained in the filter can be any agent that has antibacterial affect (see claim 3 above)). Yamagata [0009] also teaches 0.01 to 10% by weight of the antibacterial agent can be applied to the filter paper. Phenoxyethanol has a molecular weight of 138.16g/mol. Applicant discloses using 20-500 µL of urine, therefore: 138.16g/mol x 0.01g/mol = 13.86g/mol which is within the claimed content. Regarding claim 5, as mentioned above, Yamagata teaches the reagent according to claim 1 (see above). This claim merely recites an intended use of the claimed invention. The reagent of Yamagata is fully capable of preserving various urine specimens, including the claimed urine specimen, since Yamagata discloses every necessary component. Thus, Yamagata meets the limitations of the claim. See MPEP 2114. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEX RAMIREZ whose telephone number is (571)272-9756. The examiner can normally be reached Monday - Friday 8:00 - 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Capozzi can be reached at (571) 272-1295. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.R./Examiner, Art Unit 1798 /CHARLES CAPOZZI/Supervisory Patent Examiner, Art Unit 1798
Read full office action

Prosecution Timeline

Apr 28, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594550
BIOLOGICAL SAMPLE HOLDING CONTAINER AND BIOLOGICAL SAMPLE HOLDING METHOD
2y 5m to grant Granted Apr 07, 2026
Patent 12584832
Low-Energy Consumption Solvent Dilution Device For Pre-Treating Sample
2y 5m to grant Granted Mar 24, 2026
Patent 12577343
Peptide-Imprinted Conductive Polymer and Use Thereof
2y 5m to grant Granted Mar 17, 2026
Patent 12566154
Purification System for Nitrogen Gas and Xenon Gas in Water and Isotope Static Analysis Method Thereof
2y 5m to grant Granted Mar 03, 2026
Patent 12560481
METHODS OF MODIFYING A LIQUID SAMPLE CONTAINING AN ANALYTE SO AS TO INCREASESERS SIGNAL INTENSITY OF THE ANALYTE, AS WELL AS A PROBE FOR REMOTE SENSING OF AN ANALYTE USING SERS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.3%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 114 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month